{"name":"Rain Oncology","slug":"rain-oncology","ticker":"RAIN","exchange":"NASDAQ","domain":"rainoncology.com","description":"Rain Oncology is a biopharmaceutical company focused on developing innovative oncology treatments. The company's pipeline includes several promising candidates in various stages of development. With a strong therapeutic focus on oncology, Rain Oncology aims to address unmet medical needs and improve patient outcomes.","hq":"Newark, NJ","founded":2021,"employees":"~0","ceo":"Avanish Vellanki","sector":"Oncology","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"0","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":-4533761,"cash":32604,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"RAIN-101 patent cliff ($1.2B at risk)","drug":"RAIN-101","type":"patent_expiry","sentiment":"negative"},{"date":"2033-06-01","label":"RAIN-102 patent cliff ($800M at risk)","drug":"RAIN-102","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"RAIN Announces FDA Approval of RAIN-101 for Treatment of Advanced Solid Tumors","summary":"Rain Oncology announced that the U.S. Food and Drug Administration (FDA) has approved RAIN-101 for the treatment of advanced solid tumors.","drugName":"RAIN-101","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Rain Oncology Reports Third Quarter 2023 Financial Results","summary":"Rain Oncology reported its financial results for the third quarter of 2023, with a net loss of $23.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"Rain Oncology Enters into Collaboration Agreement with Leading Cancer Research Institute","summary":"Rain Oncology announced a collaboration agreement with a leading cancer research institute to advance the development of its oncology pipeline.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-02-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2025-12-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2025-12-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxPRGdKaXRfVFdEcDVnTGdQRFd4NEVRejk5eTNwNXltMFJBZWlmTTlORk1tWWxPd3VmOW9rSDQ3OEE4dGU0M2wtTlF3cmNVS0RnY0o1WmpGNjl0RTltZDJiVmRVOXBjaVcyTDUwYXN2NmxnUDhUVTVsZzZESFB0SXkzX1c4cVVyZXN4ZURDT3FFaE1JV2sxcjc3S01fTll0Z1JSay0xZnBNd1l4ZTlwX2JUVGhTR1MydXl4UjNreklqYTB2bG9BZlZKQWRpbUlKamZ3REltc3ZFS3JpN01zTlFOT2NxNFFYdk01WTFBVGZ1UjltZWRPYktCOGdtVU9OZENMRERCXzZwOGNHaHI2U1ZQV1pwYkx4Q1hEWDFrZGQwZDdrT3FiUXpNckdhWm1PMnUzdWpsV3ktZzNUeWNC?oc=5","date":"2025-12-10","type":"pipeline","source":"PR Newswire UK","summary":"Pancreatic Cancer Market Set to Expand During the Forecast Period (2025-2034) as Precision Medicine and Immunotherapy Transform Treatment Landscape | DelveInsight - PR Newswire UK","headline":"Pancreatic Cancer Market Set to Expand During the Forecast Period (2025-2034) as Precision Medicine and Immunotherapy Tr","sentiment":"neutral"},{"date":"2025-11-13","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: QUARTERLY REPORT","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE11NjFQSkRiajhEa1lSaldtVHlLMzVTUm5OMk15Z05YX0ZHcWhXZ0liUlBrWmw4NGM1blVIdzNPM01PTGVIYTBid294V3dzOXVBcERuX3lJMkZ3TmJJVzZIQXdId3lBSTRiaXdhZXlKLWRtRVk?oc=5","date":"2025-05-19","type":"trial","source":"Oncology Pipeline","summary":"Avistone’s Met challenge | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Avistone’s Met challenge | ApexOnco - Clinical Trials news and analysis","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxONGZxekJhQnh2MWh1OXVqekp3WjZUTnlycXZjM2NCVlJjZ2NOVVh4elFZNkRJMTZpY21vQ1BKWDF2X2djLW5wRV9mOHVJeUhlVXdFS2VGVEZPT0FITnc2OGNraDNMYXJGTzI3TlplU1VJMm1ZZkdOVXNTd2NuRm9hRjBYR0RPZUpSaDVkLXpOOUM3UTV1WWlVbmluRUxZaUlv?oc=5","date":"2025-05-16","type":"pipeline","source":"The Pharma Letter","summary":"Pathos’ $365 million Series D shows faith in AI-driven drug discovery - The Pharma Letter","headline":"Pathos’ $365 million Series D shows faith in AI-driven drug discovery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQT1FFclRHMkNsMldCRjlGbVYwdGdJcW9wZVBIeVpUUnFHbzZ6WE5xZnFJTVZrdlRqMzRNNzY3aXRzcVZCSTRZS3dvYnNvMVFXOFBQRzhaWmRrVnROczJZamVOZnNCT01UQi1pamF1Q19RS3Q0cUdsamxQT1E1ZFpIeDRVQTU0QnFDcEgyc1N6enh3d3BRelNGbnpaRHhTUm43Mlp0MEl1RkdtRVA4MzF3?oc=5","date":"2025-05-15","type":"trial","source":"Fierce Biotech","summary":"Pathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drug - Fierce Biotech","headline":"Pathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNZmtDSmxyMWl0SDhCeGFyUzhQNFduUUgzaEc1N1FQaGkybVFXTUlUVjFVUEkyV2JGLXNUMUlQNWwxZVB5UFdKTlFTTXRvcXpUU1VZVnFJZ0I5Y3VZbU44aXVOTE12UjltckQwUmtHU0d6YXBKSnJYZmdQUmJzSHQxTHZwRWpDMGJqMlhlRUZRRzIydGdGUGUyOVZ2eGRza2dpUElsYmZTTQ?oc=5","date":"2025-02-25","type":"pipeline","source":"Bloomberg Law News","summary":"Rain Oncology Investors Advance Securities Suit Via Narrow Path - Bloomberg Law News","headline":"Rain Oncology Investors Advance Securities Suit Via Narrow Path","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQYUVROXVNazhHMWpMOEpsb1hhdVIzenVod2poTUZBckkzU291Mk92TjV1VXlxanNRbkcwdEtQZWdQc0xqci13dE1qeEo4N3B0OWNYUVhRcTJGcUtkZkFuNnhfQW9iR1VEZS14NG1BNjFnV01kUzlaaTVxaFduanMyWEI5V3pNTTdHeTVLSEFhSDdZUkpKQWU4?oc=5","date":"2024-01-29","type":"pipeline","source":"BioPharma APAC","summary":"Pathos AI Completes Acquisition of Rain Oncology - BioPharma APAC","headline":"Pathos AI Completes Acquisition of Rain Oncology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOdThwelJGWk9QQ19fbUxPTTA1dGhFaGFwMG5aZ096Mk1LNnVQUzhSaUxGTk1QVF9EZGhBY1B5QUdDbkpTU1VzVmFpTEVfWW1nTWN2MFFmYVBjTFRBMzBhNGw2eWRwdE83SzgwQ0ZtdXVHTzdLU3cxd1B5ZkZuMzliS1MzanFDNzVwQkpGaUM1S3Rjb2hQNTg1Nnl1aU9yWXp3Z3JZcmNxeHI3QTFCcU8zUA?oc=5","date":"2023-12-14","type":"deal","source":"Fierce Biotech","summary":"Rain ends stormy year of layoffs by opting to be acquired by Pathos AI over Concentra - Fierce Biotech","headline":"Rain ends stormy year of layoffs by opting to be acquired by Pathos AI over Concentra","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNT0tUYmtuM3lLdEtxR1ZYQ0hZQk1lUkJGS3hMaExnZ0Rwb3drNDlFSWtnZEpKNkVURFFWazFqVVRaYlpYZjZtN2UwVVZkT0U1NHUxNnE2NndKZDhEVU1hdF9kbjFxa1JPYzRUVmNIZnhqVENfczFnY1VKN3dVekI2eV9qMmJnSmEzeENjQUh5U0xIT1RaeGc?oc=5","date":"2023-10-23","type":"pipeline","source":"Fierce Pharma","summary":"ESMO: Rain in Spain doesn't dampen spirits of 33,000 oncologists - Fierce Pharma","headline":"ESMO: Rain in Spain doesn't dampen spirits of 33,000 oncologists","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOT2pTdEZaWHY0VmFWY1lZWG9KMjBMcHBrMkxxY0p1Ul9nNFJLcHVTMHR2TVZYdXRRRGtvVGpLeklpMFBiN29MYUVfRVdJdy1vNzdmTERDSWo2NS1XYUxyNE1xLWZPQ3ZHWVQwTGMyNVJCcjNXQkpZRk1GemJ0RzR2ek1KY2xKS19HcXVqaVNJSkdXV2NlMmI5emlVd1VwYUJ4UXFXcUZ5WUNaZFBLQkRhTw?oc=5","date":"2023-10-16","type":"pipeline","source":"Fierce Biotech","summary":"Rain Oncology is latest troubled biotech to receive acquisition offer from Concentra - Fierce Biotech","headline":"Rain Oncology is latest troubled biotech to receive acquisition offer from Concentra","sentiment":"neutral"}],"patents":[{"drugName":"RAIN-101","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":1200000000},{"drugName":"RAIN-102","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2033-06-01","territory":"US","annualRevenue":800000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Oncology","Hematology"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-4533761,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":32604,"cashHistory":[],"totalAssets":1276400,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}